Adjunctive Cannabidiol Oral Solution vs Standard of Care in Infants with Tuberous Sclerosis Complex and Inadequately Controlled Seizures

Phase 3, randomised, open-label trial in tuberous sclerosis complex (TSC) and epilepsy comparing Cannabidiol + standard-of-care antiseizure medication with Standard-of-care antiseizure medication alone (2 arms). Primary endpoint: Safety and tolerability during 17-week treatment period (Part A).